Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Accumulated Expenses (2023 - 2025)

CG Oncology (CGON) has disclosed Accumulated Expenses for 3 consecutive years, with $24.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 65.07% year-over-year to $24.2 million, compared with a TTM value of $24.2 million through Dec 2025, up 65.07%, and an annual FY2025 reading of $24.2 million, up 65.07% over the prior year.
  • Accumulated Expenses was $24.2 million for Q4 2025 at CG Oncology, up from $20.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $24.2 million in Q4 2025 and bottomed at $5.1 million in Q1 2024.
  • Average Accumulated Expenses over 3 years is $14.7 million, with a median of $14.7 million recorded in 2024.
  • The sharpest move saw Accumulated Expenses soared 40.43% in 2024, then surged 222.36% in 2025.
  • Year by year, Accumulated Expenses stood at $10.4 million in 2023, then skyrocketed by 40.43% to $14.7 million in 2024, then soared by 65.07% to $24.2 million in 2025.
  • Business Quant data shows Accumulated Expenses for CGON at $24.2 million in Q4 2025, $20.4 million in Q3 2025, and $23.0 million in Q2 2025.